Trial Profile
Impact of Baseline NRTI Resistance Mutations on Virological Suppression of HIV-1 Infected Patients Treated by Elvitegravir/Cobicistat/Emtricitabine/Tenofovir
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Mar 2016
Price :
$35
*
At a glance
- Drugs Elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 02 Mar 2016 New trial record